Baxter Drug Recall | Safety Guide for Patients & Providers

Baxter International Recalls Multiple Injectable Solutions

Baxter International Inc. has initiated a voluntary nationwide recall for three types of injectable medications due to potential contamination with fiberglass and stainless steel particles. The affected products include 70% Dextrose Injection, 0.9% Sodium Chloride Injection, and Anticoagulant Sodium Citrate Solution. These substances are typically provided to patients requiring intravenous nutrition, hydration, or electrolyte balance. The Food and Drug Administration issued public notices on August 25 and August 26 regarding the hazards associated with these materials.

The 70% Dextrose Injection is essential for patients unable to ingest calories orally or through traditional feeding tubes. One specific lot was identified as carrying stainless steel fragments, which pose significant risks to vascular health. Injecting these particles into the bloodstream may induce blockages, trigger blood clots in the lungs, or disrupt circulation to critical organs. According to FDA documentation, such events can lead to severe physiological damage or life-threatening complications. While the product saw distribution across Alabama, Georgia, and Tennessee during late July 2026, clinical reports of adverse reactions remain at zero.

Understanding the Contamination Risks

Beyond the metal contaminants, the 0.9% Sodium Chloride Injection has been flagged for potential fiberglass presence. Healthcare facilities use this solution for rehydration, blood transfusions, and hemodialysis procedures. Two distinct lots distributed between July 31 and August 3 are part of the recall effort. Medical professionals warn that fiberglass in an intravenous line acts as a foreign body, capable of causing localized inflammation, vein irritation, and systemic clotting issues.

Distribution for the sodium chloride injection spans a wide geographic footprint, impacting Florida, Illinois, Indiana, Louisiana, Maryland, Missouri, North Carolina, New Jersey, Nevada, New York, Ohio, South Carolina, Texas, and Virginia. A third product, the Anticoagulant Sodium Citrate Solution, was also pulled from the market. This recall appears highly localized, with the FDA reporting that distribution was limited to a single customer. No injuries have been linked to any of the three recalled products at this time.

Guidance for Healthcare Providers and Home Patients

Patients or caregivers managing at-home medical supplies should verify the labels against the official FDA recall list immediately. The 70% Dextrose Injection is identified by product code 2B0296H and lot number Y495066, expiring on July 31, 2027. The 0.9% Sodium Chloride Injection is identified by code 2B1323Q, lot number Y495523, with an expiration date of October 31, 2027. These products were packaged in Viaflex plastic containers.

If you possess these items, do not attempt to use them. Contact the original distributor or healthcare facility to arrange for return or disposal according to safety protocols. Baxter Healthcare Center for Service is reachable at 888-229-0001 for specific inquiries regarding the recall process. Clinicians who suspect adverse events must report them to the FDA MedWatch program via their online portal or telephone reporting line. The pharmaceutical industry remains under strict scrutiny regarding the integrity of intravenous supply chains, and this incident underscores the necessity of rigorous quality control measures.